Enterprise Value
79.26M
Cash
116.2M
Avg Qtr Burn
-13.29M
Short % of Float
2.61%
Insider Ownership
0.88%
Institutional Own.
64.99%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LYR-210 (anti-inflammatory implantable drug matrix) Details Rhinosinusitis, Chronic rhinosinusitis, Neurological disorder | Phase 3 Data readout | |
LYR-220 (Long-acting Mometasone Furoate) Details Chronic rhinosinusitis | Phase 2 Update |